Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Apr;25(4):433–437. doi: 10.1128/aac.25.4.433

Pharmacokinetics of vancomycin in patients with various degrees of renal function.

G R Matzke, R W McGory, C E Halstenson, W F Keane
PMCID: PMC185546  PMID: 6732213

Abstract

The pharmacokinetics of vancomycin were characterized in 56 patients with different degrees of renal function after an intravenous dose of 18.4 +/- 4.7 mg kg-1 (mean +/- standard deviation). Seven subjects had a creatinine clearance (CLCR) of greater than 60 ml min-1 (group I), 13 had a CLCR of 10 to 60 ml min-1 (group II), and 36 had a CLCR of less than 10 ml min-1 (group III). Serial serum samples (range, 3 to 8) were collected during the 168 h after drug administration. The serum concentration-time profile in all patients demonstrated monoexponential decay. The mean half-lives were 9.1, 32.3, and 146.7 h in groups I, II, and III, respectively. A significant decline in serum clearance (CLS) was also noted (62.7 to 28.3 to 4.87 ml min-1 in groups I, II, and III, respectively). The steady-state volume of distribution varied from 0.72 to 0.90 liter kg-1. There was no significant relationship between the steady-state volume of distribution and CLCR. The observed relationship between CLS and CLCR (CLS = 3.66 + 0.689 CLCR; r = 0.8807) can be utilized to devise dosage schedules for patients with any degree of renal impairment. This relationship was utilized to develop a nomogram for initial and maintenance dosing of vancomycin.

Full text

PDF
433

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  2. Eykyn S., Phillips I., Evans J. Vancomycin for staphylococcal shunt site infections in patients on regular haemodialysis. Br Med J. 1970 Jul 11;3(5714):80–82. doi: 10.1136/bmj.3.5714.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gambertoglio J. G., Wilson W. R., Van Scoy R. E. Dosage of vancomycin. Mayo Clin Proc. 1978 Mar;53(3):197–198. [PubMed] [Google Scholar]
  4. Geraci J. E., Hermans P. E. Vancomycin. Mayo Clin Proc. 1983 Feb;58(2):88–91. [PubMed] [Google Scholar]
  5. Lindholm D. D., Murray J. S. Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis. N Engl J Med. 1966 May 12;274(19):1047–1051. doi: 10.1056/NEJM196605122741902. [DOI] [PubMed] [Google Scholar]
  6. Moellering R. C., Jr, Krogstad D. J., Greenblatt D. J. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med. 1981 Mar;94(3):343–346. doi: 10.7326/0003-4819-94-3-343. [DOI] [PubMed] [Google Scholar]
  7. Morris A. J., Bilinsky R. T. Prevention of staphylococcal shunt infections by continuous vancomycin prophylaxis. Am J Med Sci. 1971 Aug;262(2):87–92. doi: 10.1097/00000441-197108000-00003. [DOI] [PubMed] [Google Scholar]
  8. Nielsen H. E., Hansen H. E., Korsager B., Skov P. E. Renal excretion of vancomycinin in kidney disease. Acta Med Scand. 1975 Apr;197(4):261–264. doi: 10.1111/j.0954-6820.1975.tb04914.x. [DOI] [PubMed] [Google Scholar]
  9. Nielsen H. E., Sørensen I., Hansen H. E. Peritoneal transport of vancomycin during peritoneal dialysis. Nephron. 1979;24(6):274–277. doi: 10.1159/000181735. [DOI] [PubMed] [Google Scholar]
  10. Rotschafer J. C., Crossley K., Zaske D. E., Mead K., Sawchuk R. J., Solem L. D. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother. 1982 Sep;22(3):391–394. doi: 10.1128/aac.22.3.391. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES